Advertisement


Jame Abraham, MD, on Breast Cancer: Expert Perspective on the MONARCH 2 Trial

2017 ASCO Annual Meeting

Advertisement

Jame Abraham, MD, of the Cleveland Clinic, gives his views on findings on abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. (Abstract 1000)



Related Videos

Supportive Care
Issues in Oncology

Gary Rodin, MD, on Advanced Cancer: The CALM Psychological Intervention

Gary Rodin, MD, of the University of Toronto, discusses study findings on a systematic approach to alleviating distress and managing predictable challenges. (Abstract LBA10001)

Lung Cancer

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial

Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)

Issues in Oncology

Elizabeth J. Shpall, MD, and Nina Shah, MD—Mentor and Mentee: A Conversation

Elizabeth J. Shpall, MD, of The University of Texas MD Anderson Cancer Center, and recipient of the 2017 Women Who Conquer Cancer Mentorship Award, discusses promoting women in oncology with Nina Shah, MD, of the University of California, San Francisco, the protégé who nominated Dr. Shpall for this recognition.

Genomics/Genetics

Olivier Tredan, MD, PhD, on Advanced Refractory Cancer and Molecular Screening

Olivier Tredan, MD, PhD, of the Centre Léon Bérard, discusses results from ProfilER, a study that explored the use of cancer cell genomic alterations to guide treatment in patients with advanced refractory cancer. (Abstract LBA100)

Colorectal Cancer

John Marshall, MD, and Qian Shi, PhD, on Colon Cancer: Results of the IDEA Trial

John Marshall, MD, of Georgetown University, and Qian Shi, PhD, of the Mayo Clinic, discuss study findings on shortening the duration of adjuvant oxaliplatin-based therapy, linked to neurotoxicity, for patients with stage III colon cancer. (Abstract LBA1)

Advertisement

Advertisement




Advertisement